What We Do
Who We Are

    BTTC NEWS

    BTTC Holds Annual Meeting

    The Brain Tumor Trials Collaborative held a productive meeting on March 31, 2017 at the National Institutes of Health (NIH). At the meeting, which included neuro-oncologists from 26 hospitals across the United States, BTTC members shared information about current and upcoming clinical trials.

     

    For more on this story, click here.

     

    BTTC Clinical Trial Re-opened for Enrollment

    The Everolimus/Sorafenib (BTTC 09-01) study will evaluate the occurrence of symptoms and their relations to disease progression, as well as the tolerance to treatment regimen. A phase I-II trial everolimus and sorafenib in patients with recurrent high-grade gliomas.

     

    For more on this story, click here.

     

    BTTC Investigators Publish Paper in Journal of Neuro-Oncology

    The Brain Tumor Trials Collaborative investigators publish the BTTC 08-01 results in the October 2015 issue of the Journal of Neuro-Oncology.

     

    For more on this story, click here.

    OUR INSTITUTIONS

    Each of the participating BTTC institutions are committed to discovering new and effective therapies for the treatment of patients with brain tumors with compassion and understanding. BTTC is a network of medical centers with the expertise and strong desire to participate in state-of-the-art clinical trials investigating new treatments for malignant brain tumors.

     

    For the participating BTTC institutions, click here.

     

     

    OUR DOCTORS

    The doctors who are participating in the BTTC are compassionate experts in their respective fields and are dedicated to finding new and effective therapies for the treatment of patients with brain tumors.
     
    For the participating BTTC doctors, click here.